Hong Guo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Hong Guo has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
- Bing Li
Department of Chemical & Materials Engineering The University of Auckland Auckland New Zealand
1 shared publication - Chengjie Wei
Laboratory of Animal (Poultry) Genetics Breeding and Reproduction, Ministry of Agriculture, Institute of Animal Science Chinese Academy of Agricultural Sciences (CAAS) Beijing China
1 shared publication - Chengshi He
Respiratory Medicine, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu 610072, China
1 shared publication - Chunmei Wang
Aerospace Information Research Institute, Chinese Academy of Sciences, Beijing, China
1 shared publication - Danqing Luo
Department of Rehabilitation, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu 610072, China
1 shared publication - Di Zhang
Rehabilitation Department, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China
1 shared publication
Latest Publications
- Open Access
- 1 January 2024
- Published by Wiley in Canadian Respiratory Journal
- Vol. 2024 (1) , 8827810
The Effect of Fuzheng Yiai Decoction on the Transdifferentiation of Lung Adenocarcinoma in EGFR‐TKI‐Resistant Mice
This study aimed to investigate the effect of Fuzheng Yiai Decoction (FZYA) on epidermal growth factor receptor‐tyrosine kinase inhibitor (EGFR‐TKI) drug resistance in lung adenosquamous carcinoma (ASC). The expression of thyroid transcription factor 1 (TTF1) and p63 in tumor cells was observed by immunofluorescence staining. Meanwhile, 25 nude mice successfully inoculated with the human lung ASC cell line NCI‐H596 were randomly divided into five groups, namely, the model, gefitinib, low‐, medium‐, and high‐dose FZYA with gefitinib groups. After four weeks of daily intragastric administration of the various treatments, the tumor weight and volume inhibition rates were calculated. The positive expression rate and protein expression of TTF1 and p63 in mouse tumor tissues were evaluated by immunohistochemistry and western blot assays. The results showed that the adenocarcinoma part and the squamous cell carcinoma part of the lung tissue were not either one or the other, and each had unique biological behavior patterns. In terms of the tumor volume and weight, gefitinib treatment along with FZYA reduced the acquired resistance of EGFR‐TKIs in lung ASC, and its inhibitory effect was superior to EGFR‐TKI (gefitinib) treatment alone. Moreover, it was discovered that FZYA inhibited the pedigree transformation among cancer subtypes due to EGFR‐TKI treatment. In conclusion, the application of FZYA inhibited the pedigree transformation among lung cancer subtypes, thus increasing the tumor inhibitory effect and decreasing the EGFR‐TKI drug resistance of tumor cells.
- 1 January 2024
- Published by Wiley in Canadian Respiratory Journal
- Vol. 2024 (1) , 8827810
Open AccessThe Effect of Fuzheng Yiai Decoction on the Transdifferentiation of Lung Adenocarcinoma in EGFR‐TKI‐Resistant Mice
This study aimed to investigate the effect of Fuzheng Yiai Decoction (FZYA) on epidermal growth factor receptor‐tyrosine kinase inhibitor (EGFR‐TKI) drug resistance in lung adenosquamous carcinoma (ASC). The expression of thyroid transcription factor 1 (TTF1) and p63 in tumor cells was observed by immunofluorescence staining. Meanwhile, 25 nude mice successfully inoculated with the human lung ASC cell line NCI‐H596 were randomly divided into five groups, namely, the model, gefitinib, low‐, medium‐, and high‐dose FZYA with gefitinib groups. After four weeks of daily intragastric administration of the various treatments, the tumor weight and volume inhibition rates were calculated. The positive expression rate and protein expression of TTF1 and p63 in mouse tumor tissues were evaluated by immunohistochemistry and western blot assays. The results showed that the adenocarcinoma part and the squamous cell carcinoma part of the lung tissue were not either one or the other, and each had unique biological behavior patterns. In terms of the tumor volume and weight, gefitinib treatment along with FZYA reduced the acquired resistance of EGFR‐TKIs in lung ASC, and its inhibitory effect was superior to EGFR‐TKI (gefitinib) treatment alone. Moreover, it was discovered that FZYA inhibited the pedigree transformation among cancer subtypes due to EGFR‐TKI treatment. In conclusion, the application of FZYA inhibited the pedigree transformation among lung cancer subtypes, thus increasing the tumor inhibitory effect and decreasing the EGFR‐TKI drug resistance of tumor cells.
- Open Access
- 1 January 2016
- Published by Aerospace Information Research Institute, Chinese Academy of Sciences in National Remote Sensing Bulletin
- Vol. 20 (5) , 781-793
40年的跨越—中国航天遥感蓬勃发展中的“三大战役”
- 1 January 2016
- Published by Aerospace Information Research Institute, Chinese Academy of Sciences in National Remote Sensing Bulletin
- Vol. 20 (5) , 781-793
Open Access40年的跨越—中国航天遥感蓬勃发展中的“三大战役”